0G99.L

Oxurion NV [0G99.L] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

0G99.L Stock Summary

In the News

0G99.L Financial details

Company Rating
-
Market Cap
901.48K
Income
-41.74M
Revenue
772.5K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
05 Apr 2024
P/E
-0.01
Forward P/E
-
PEG
0
P/S
4.07
P/B
-0.02
P/C
-
P/FCF
-0.18
Quick Ratio
0.35
Current Ratio
0.4
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.15
EPS next Y
-
EPS next Q
-
EPS this Y
-51.32%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-18.2%
Revenue last 5Y
-35.48%
Revenue Q/Q
100%
EPS Q/Q
100%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-235%
ROE
421%
ROC
2.29%
Gross Margin
15%
Oper. Margin
-3035%
Profit Margin
-5403%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0-0.0122
52W High
-
52W Low
-
RSI
-
Rel Volume
-
Avg Volume
8.96K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.508
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
TL0.DE
V
VTI
APC.DE
M&M.NS
Same Sector
002432.SZ
URGN
DANE.TA
0RKL.L
SAKAR.NS
Check Those
MCB.TO
0IC8.L
GRIO.L
HL-PB
FNOVA-B.ST
Similar Market Cap
SMLE
OCTX
AMC.L
AMPE
MNRG.L

Company Profile

Healthcare Medical - Pharmaceuticals
  • Volume Average 8.96K
  • Market Capitalization 901.48K
  • Employee 20
  • CEO Mr. Pascal Ghoson
  • Headquarters Leuven,BE
  • IPO Date 2008-08-06
  • Website https://www.oxurion.com

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.